FR-167356

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H525105

CAS#: 174185-16-1

Description: FR-167356 is a novel inhibitor of vacuolar ATPase. It has been proposed as a drug target in lytic bone diseases. Studies suggest that the key issue regarding the therapeutic usefulness of V-ATPase inhibitors is selective inhibition of osteoclast V-ATPase.


Chemical Structure

img
FR-167356
CAS# 174185-16-1

Theoretical Analysis

Hodoodo Cat#: H525105
Name: FR-167356
CAS#: 174185-16-1
Chemical Formula: C19H17Cl2NO3
Exact Mass: 377.06
Molecular Weight: 378.250
Elemental Analysis: C, 60.33; H, 4.53; Cl, 18.75; N, 3.70; O, 12.69

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: FR-167356; FR167356; FR 167356; UNII-XF02B1HC8R.

IUPAC/Chemical Name: Benzamide, 2,6-dichloro-N-(3-(1-hydroxy-1-methylethyl)-2-methyl-7-benzofuranyl)-

InChi Key: GCAOVMKRBUCSET-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H17Cl2NO3/c1-10-16(19(2,3)24)11-6-4-9-14(17(11)25-10)22-18(23)15-12(20)7-5-8-13(15)21/h4-9,24H,1-3H3,(H,22,23)

SMILES Code: Cc1c(c2cccc(c2o1)NC(=O)c3c(cccc3Cl)Cl)C(C)(C)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 378.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Nishisho T, Hata K, Nakanishi M, Morita Y, Sun-Wada GH, Wada Y, Yasui N, Yoneda T. The a3 isoform vacuolar type H⁺-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res. 2011 Jul;9(7):845-55. doi: 10.1158/1541-7786.MCR-10-0449. Epub 2011 Jun 13. PubMed PMID: 21669964.

2: Morissette G, Ammoury A, Rusu D, Marguery MC, Lodge R, Poubelle PE, Marceau F. Intracellular sequestration of amiodarone: role of vacuolar ATPase and macroautophagic transition of the resulting vacuolar cytopathology. Br J Pharmacol. 2009 Aug;157(8):1531-40. doi: 10.1111/j.1476-5381.2009.00320.x. Epub 2009 Jul 7. PubMed PMID: 19594752; PubMed Central PMCID: PMC2765325.

3: Morissette G, Lodge R, Marceau F. Intense pseudotransport of a cationic drug mediated by vacuolar ATPase: procainamide-induced autophagic cell vacuolization. Toxicol Appl Pharmacol. 2008 May 1;228(3):364-77. doi: 10.1016/j.taap.2007.12.031. Epub 2008 Jan 26. PubMed PMID: 18295291.

4: Niikura K, Takeshita N, Takano M. A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application. J Bone Miner Res. 2005 Sep;20(9):1579-88. Epub 2005 May 31. PubMed PMID: 16059630.

5: Niikura K, Takano M, Sawada M. A novel inhibitor of vacuolar ATPase, FR167356, which can discriminate between osteoclast vacuolar ATPase and lysosomal vacuolar ATPase. Br J Pharmacol. 2004 Jun;142(3):558-66. Epub 2004 May 17. PubMed PMID: 15148249; PubMed Central PMCID: PMC1574973.